One-carbon therapeutics AB is discussing the ODIN trial with several leading clinical sites at the upcoming ESMO meeting in Barcelona. The ODIN trial is a first-in-human, first-in-class clinical phase 1/2 trial with MTHFD1/2 inhibitor TH9619 in selected solid cancers.
Dr Eva Ehrnrooth, MD PhD to join One-carbon Therapeutics AB management team as interim CMO
Dr Eva Ehrnrooth (MD PhD) brings + 20 years of
